Poolbeg Pharma oral vaccine programme moves forward

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with high unmet medical needs, announces an update to its Oral Vaccine Programme following the award of non-dilutive grant funding by the Irish Government’s Disruptive Technologies Innovation Fund (DTIF) in November 2022, as part of the Poolbeg led EncOVac Consortium. Having finalised the research plan and all consortium members completing the Consortium and Grant Agreements, the EncOVac Consortium parties are now entering the next phase to commence the validation of the encapsulation process. The validation is expected to complete in H2 2023.

Taking place over three years, the EncOVac Consortium is funded to develop a Phase I clinical trial ready oral vaccine candidate. The agreed research plan includes several stages of work and once the encapsulation process, developed by AnaBio Technologies, has been successfully validated, the consortium will proceed to encapsulate vaccine antigen candidates developed by Associate Professor Siobhán McClean at University College Dublin together with adjuvants identified by Professor Ed Lavelle at Trinity College Dublin. This oral vaccine candidate will then complete all required non-clinical testing in preparation for a Phase I clinical trial.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Poolbeg Pharma

More articles like this

AI revolutionises drug discovery and pharmaceutical research

The future of drug discovery and pharmaceutical research is being reshaped by artificial intelligence (AI), heralding a new era of speed, efficiency, and precision. AI’s potential to accelerate drug development, from molecular prediction to optimised design

Poolbeg Pharma relocates to new London headquarters at 40 Bank Street

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the Company has changed its registered address to 40 Bank Street,

Innovative approaches at Poolbeg Pharma

Poolbeg Pharma plc is dedicated to the development and commercialisation of innovative medicines, particularly those targeting diseases with high unmet medical needs, including rare and orphan diseases. The company’s strategy revolves around developing its promising clinical

GLP-1 receptor agonists transform diabetes treatment

GLP-1 (glucagon-like peptide-1) and its receptor agonists (GLP-1RAs) have emerged as a groundbreaking class of drugs in diabetes management, particularly due to their impressive efficacy in reducing obesity, a key factor in type 2 diabetes. Jeremy

AI revolutionising the pharmaceutical industry

The rapid advancement of artificial intelligence (AI) is making significant strides in the pharmaceutical sector. Since its inception, this industry has embraced AI and machine learning, continuing its legacy of innovation. The integration of these technologies

Poolbeg Pharma publishes Annual Report and AGM Notice

Poolbeg Pharma plc (LON: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has confirmed that the Company’s Annual Report and Accounts for the period ended

Poolbeg Pharma expands treatment into new markets

Poolbeg Pharma said it had made progress last year in expanding its treatments into new markets, with significant pipeline advancements and strategic deals. The company said it had made a strategic expansion into the treatment of

Poolbeg Pharma granted significant POLB 001 patent in United States

Poolbeg Pharma plc (LON:POLB, OTCQB:POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that, further to its announcement on 20 March 2024, the Company has received the fully granted